Join today and have your say! It’s FREE!
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Alpha Cognition Inc ACOG

Alpha Cognition Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease and Cognitive Impairment with mild Traumatic Brain Injury (mTBI). The Company’s pipeline includes ALPHA-1062, ALPHA-0602, and ALPHA-0702 and ALPHA-0802 (GEMs). The Company’s ALPHA-1062... see more

Bullboard (NDAQ:ACOG)

View:
Post by G1945Von Jan 06, 2025 9:07am

Press Release-Jan 6, 2025

Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer's Long-Term Care Market During Investor Update Call G1945V
Post by TrevorAbeson Jul 30, 2024 8:04am

FDA approves Alpha Cognition's Zunveyl to treat Alzheimer's

Growth runway activated: https://stockhouse.com/news/the-market-online-news/2024/07/29/fda-approves-alpha-cognition-s-zunveyl-to-treat-alzheimer-s-disease
Post by G1945Von Jul 29, 2024 11:09am

(FDA) has granted approval for ZUNVEYL® AKA, ALPHA-1062,

https://www.businesswire.com/news/home/20240729327804/en/ G1945V
Post by TheMediaon Mar 29, 2024 2:53pm

Ouch!

Not sure what this poor company paid the duds @ Equity Guru to pump the stock the results from the Equity Guru will be ZERO! Stop paying Chris Parry to do nothing.
Post by G1945Von Aug 14, 2023 5:13pm

Business Wire:

Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer's Disease G1945V
Post by StreamlineCapon Jul 22, 2023 1:08am

Up 64% this month...

Is there any news with the NDA being filed? Stock is trading like the company is breathing new life. 
Post by G1945Von Sep 02, 2022 12:37pm

Zacks Small-Cap Research

September 2, 2022 John D. Vandermosten, CFA https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_09022022_ACOGF_Vandermosten.pdfZacks G1945V
Post by culturedpiggy01on Apr 22, 2022 5:49pm

$ACOG.v announces new CFO and additions to the board

$ACOG.v recently announced the appointment of Don Kalkofen as Chief Financial Officer (CFO) and Michael McFadden, $ACOG ‘s CEO, to the board of directors https://ca.finance.yahoo.com/news/alpha ...more  
Post by StockHawk1on Apr 20, 2022 5:26pm

$ACOG gets positive preclinical results for ALPHA-0602 drug

For those interested in the biopharma space, Alpha Cognition Inc. ($ACOG.v $ACOGF) is a company working on creating medication to help those with neurodegenerative disorders. It recently announced ...more  
Comment by partystockeron Apr 19, 2022 12:42pm

RE:$ACOG appoints new CFO

Some solid gains on the chart for $ACOG.v the past few days. Shares are up a solid 13% and holding!
Post by Stockydocon Apr 18, 2022 4:29pm

$ACOG appoints new CFO

Last week, $ACOG announced they have appointed Don Kalkofen as CFO. Mr. Kalkofen has plenty of experience in the biotechnology industry and has been successful in the past serving as CFO of ...more  
Post by partystockeron Apr 17, 2022 1:30pm

$ACOG.v Updates

As Alpha Cognition (TSXV: ACOG) enters its next phase of growth, the company has appointed Don Kalkofen as CFO. Don has considerable experience in corporate finance, as well as a strong track record ...more  
The Market Update
Sorry, the video player failed to load.(Error Code: 104153)
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

Sorry, the video player failed to load.(Error Code: 104153)
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities